MARKET

ATNM

ATNM

ACTINIUM PHARMAC
AMEX

Real-time Quotes | Nasdaq Last Sale

8.10
+0.70
+9.46%
After Hours: 8.31 +0.21 +2.59% 18:24 09/21 EDT
OPEN
7.45
PREV CLOSE
7.40
HIGH
8.29
LOW
7.44
VOLUME
531.91K
TURNOVER
--
52 WEEK HIGH
13.18
52 WEEK LOW
5.70
MARKET CAP
172.78M
P/E (TTM)
-6.2418
1D
5D
1M
3M
1Y
5Y
Actinium to Present at Four Upcoming Investor Conferences
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that it will present at four upcoming investor conferences.
PR Newswire · 1d ago
48 Biggest Movers From Friday
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by AstraZeneca for patients with unresectable, stage 3 non-small cell lung cancer.
Benzinga · 1d ago
Why Actinium Pharmaceuticals' Stock Is Trading Higher Today
Actinium Pharmaceuticals (AMEX:ATNM) shares are trading higher after the company announced it completed enrollment in the pivotal Phase 3 SIERRA trial of iomab-B.
Benzinga · 6d ago
YY, NNVC and REKR among mid-day movers
Gainers: GreenSky (NASDAQ:GSKY) +53%. IronNet (NYSE:IRNT) +27%. Sphere (NASDAQ:ANY) +22%. Allied Healthcare Products (NASDAQ:AHPI) +19%. Actinium Pharmaceuticals (NYSE:ATNM) +16%. Ampio Pharmaceuticals (NYSE:AMPE) +15%. Inozyme Pharma (NASDAQ:INZY) +15%. S...
Seekingalpha · 6d ago
38 Stocks Moving In Wednesday's Mid-Day Session
Gainers Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares jumped 177.2% to $19.60 after the company announced the United States Patent and Trademark Office has issued a notice of allowance for claims related to the company's platform technology.
Benzinga · 6d ago
CTXS, ATNM and GSKY among pre market gainers
GreenSky (NASDAQ:GSKY) +48% Goldman Sachs to acquire GreenSky Birks Group (NYSE:BGI) +13%. Innate Pharma (NASDAQ:IPHA) +12% on 1H earnings. LM Funding America (NASDAQ:LMFA) +12% expands into cryptocurrency mining business MeaTech 3D (NASDAQ:MITC) +11% manu...
Seekingalpha · 6d ago
BRIEF-Actinium Completes Enrollment In The Pivotal Phase 3 Sierra Trial Of Iomab-B
reuters.com · 6d ago
Actinium Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B
/PRNewswire/ --   (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it has completed enrollment of the pivotal Phase 3 SIERRA trial for Iomab-B, an Antibody Radiation Conjugate (ARC) comprised of apamistamab, a CD45 targeting antibod...
PR Newswire - PRF · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATNM. Analyze the recent business situations of ACTINIUM PHARMAC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATNM stock price target is 32.50 with a high estimate of 45.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 42
Institutional Holdings: 23.40M
% Owned: 109.68%
Shares Outstanding: 21.33M
TypeInstitutionsShares
Increased
10
5.54M
New
5
10.91M
Decreased
6
1.59M
Sold Out
5
306.41K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.43%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Chairman/Chief Executive Officer/Director
Sandesh Seth
Chief Financial Officer
Steve O'Loughlin
Chief Technology Officer/Chief Scientific Officer
Dale Ludwig
Other
Mark Berger
Lead Director/Independent Director
C. David Nicholson
Independent Director
Jeffrey Chell
Independent Director
Ajit Shetty
Independent Director
Richard Steinhart
No Data
  • All
  • Financials
  • Insiders
More
About ATNM
Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.

Webull offers kinds of Actinium Pharmaceuticals Inc stock information, including AMEX:ATNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATNM stock methods without spending real money on the virtual paper trading platform.